Drug Trial Radar · NCT05714345
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Nov 1, 2023
Primary completion
Feb 20, 2024
Study completion Oct 28, 2024
Sponsor
- Lead sponsor
- Allogene TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the EXPAND study is to assess the safety and clinical efficacy of ALLO-647 combined with fludarabine and cyclophosphamide compared to fludarabine and cyclophosphamide alone in a lymphodepletion regimen prior to ALLO-501A CAR T therapy in adults with relapsed or refractory large B-cell lymphoma
Conditions
- Relapsed/Refractory Large B Cell Lymphoma
Interventions
ALLO-647Biological
ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
FludarabineDrug
Chemotherapy for lymphodepletion
CyclophosphamideDrug
Chemotherapy for lymphodepletion
ALLO-501AGenetic
ALLO-501A is an allogeneic CAR T cell therapy targeting CD19
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) of a Lymphodepletion Regimen Containing FCA vs FC Alone Per Independent Review CommitteeTime frame: Up to 60 months
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
University of Louisville James Graham Brown Cancer Center
Louisville, Kentucky
Universitair Ziekenhuis Brussel
Brussels, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.